Physician profile
Jonathan Packer
NPI 1316472764
$1,234.13
in general payments reported to CMS, 2019-2025
19 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.16 · 2022: $170 · 2023: $283 · 2024: $396 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.38 | 2021-2025 | Ofev |
| Abiomed | $147.02 | 2023 | Impella |
| Astrazeneca Pharmaceuticals Lp | $127.90 | 2023-2025 | Fasenra |
| Abbvie INC. | $103.16 | 2024-2025 | |
| Amgen INC. | $93.78 | 2024-2025 | Tezspire |
| Insmed, INC. | $83.45 | 2022-2024 | Arikayce |
| Olympus America INC. | $56.55 | 2024 | |
| Grifols USA, LLC | $56.45 | 2024-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $52.71 | 2022-2023 | |
| United Therapeutics Corporation | $52.10 | 2024-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $49.37 | 2024 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $41.21 | 2021-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $33.57 | 2024 | Glassia |
| Electromed, INC. | $32.84 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $26.22 | 2025 | Opsumit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.11 | 2025 | Dupixent |
| Verona Pharma, INC. | $24.48 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $20.42 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Fisher & Paykel Healthcare INC | $13.41 | 2024 | Fisher & Paykel Healthcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Packer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.